Xu et al. reviewed and summarized the role of CRISPR/Cas9 technology- associated PD-1/PD-L1 editing in tumor immunity in different types of tumors, including leukemia, multiple myeloma, breast cancer, hepatocarcinoma, lung cancer, melanoma, cervical and ovarian cancer [132]. This evidence concerns the gene CD274 and neoplasm.